Cisplatin

Introduction

Cisplatin is a platinum‑based chemotherapeutic agent that has been a cornerstone of anticancer therapy since its clinical introduction in the early 1970s. Its discovery, subsequent optimization, and widespread adoption have profoundly influenced the treatment landscape for a variety of solid tumours, including testicular, ovarian, lung, head and neck, and bladder cancers. The drug’s unique mode of action, coupled with a well‑characterized safety profile, renders cisplatin a valuable subject of study for pharmacology and pharmacy curricula.

Learning objectives for this chapter are:

• To describe the historical development and chemical synthesis of cisplatin.
• To elucidate the pharmacokinetic and pharmacodynamic principles governing cisplatin therapy.
• To explain the molecular mechanisms underlying cisplatin’s antitumour activity.
• To recognize the major toxicities associated with cisplatin use and strategies for mitigation.
• To apply knowledge of cisplatin pharmacology to clinical decision‑making in oncology practice.

Fundamental Principles

Core Concepts and Definitions

Cisplatin, chemically designated cis‑diammine(1,2‑bis(2‑chloro­acetyl)platinum(II), is a coordination complex comprising a central platinum(II) ion bound to two ammine ligands and two chloride ions arranged in a cis configuration. The cis arrangement is essential for its biological activity; the trans isomer exhibits markedly lower cytotoxicity.

Key terminology within the context of cisplatin pharmacology includes:

• Pharmacokinetics (PK): The absorption, distribution, metabolism, and excretion of the drug.
• Pharmacodynamics (PD): The relationship between drug concentration and its therapeutic or toxic effect.
• DNA cross‑linking: The covalent bonding of the drug to nucleophilic sites on DNA, leading to intra‑ and inter‑strand cross‑links.
• Nephrotoxicity: Injury to renal tubular cells, a dose‑limiting adverse effect of cisplatin.
• Ototoxicity: Damage to cochlear hair cells, resulting in sensorineural hearing loss.
• Peripheral neurotoxicity: Neuropathic pain and sensory deficits arising from dorsal root ganglion involvement.

Theoretical Foundations

The therapeutic efficacy of cisplatin rests on its ability to form covalent bonds with DNA bases, primarily guanine residues. The resulting adducts impede replication and transcription, ultimately triggering apoptosis. The kinetic inertness of the platinum center allows for selective interaction with nucleophilic sites within the nucleus, while the chloride ligands are displaced in an aqueous environment, a process governed by the following equilibrium:

PtCl₂(NH₃)₂ + 2 Cl⁻ ⇌ PtCl₄(NH₃)₂²⁻ → Pt(NH₃)₂(N₂G) + 2 Cl⁻

where N₂G represents a guanine nucleoside. The formation of intra‑strand cross‑links is predominant due to the cis configuration, whereas inter‑strand cross‑links, though less frequent, contribute to cytotoxicity.

Detailed Explanation

Pharmacokinetics

Following intravenous administration, cisplatin exhibits a biphasic distribution pattern. The initial distribution phase (t_1/2 ≈ 1–3 h) is characterized by rapid equilibration between plasma and extravascular compartments. The elimination phase (t_1/2 ≈ 30–60 h) reflects renal excretion as the primary route of elimination. Clearance (Cl) is calculated via the equation:

Cl = Dose ÷ AUC

where AUC denotes the area under the plasma concentration–time curve. The apparent volume of distribution (V_d) is typically large, reflecting extensive tissue binding. Hepatic metabolism is negligible; instead, platinum complexes undergo hydrolysis, forming active species that can be conjugated with glutathione, cysteine, and other thiols, facilitating renal excretion.

Pharmacodynamics and Dose‑Response Relationship

Therapeutic response is closely linked to the area under the concentration–time curve, with a target AUC of 20–30 mg h L⁻¹ achieving optimal tumour control in many indications. The relationship between dose and efficacy can be expressed by the following model:

E = E_max × (C_max ÷ (C_max + EC₅₀))

where E represents the pharmacologic effect, E_max the maximal effect, C_max the peak plasma concentration, and EC₅₀ the concentration producing 50 % of E_max. This sigmoidal curve reflects the saturation of DNA binding sites at higher concentrations.

Molecular Mechanisms of Action

The cytotoxic effect of cisplatin is mediated through several interrelated pathways:

1. DNA cross‑linking: Covalent bonds form at the N₇ position of guanine, generating 1,2‑intrastrand cross‑links that distort the DNA helix. This steric hindrance blocks replication fork progression and triggers the activation of DNA damage response pathways.
2. Apoptotic signalling: Persistent DNA lesions activate p53‑dependent and -independent pathways, culminating in caspase activation and programmed cell death. In p53‑deficient cells, alternative pathways involving mitochondrial outer membrane permeabilization may compensate.
3. Cell cycle arrest: The G₂/M checkpoint is frequently engaged, allowing time for repair mechanisms. Failure to repair leads to apoptosis or senescence.
4. Oxidative stress: Cisplatin can generate reactive oxygen species (ROS) through interaction with iron or other transition metals, contributing to cytotoxicity and exacerbating renal injury.

Factors Affecting Pharmacokinetics and Pharmacodynamics

Several patient‑specific and treatment‑related variables modulate cisplatin disposition and response:

• Renal function: Impaired glomerular filtration increases exposure and toxicity.
• Hydration status: Adequate intravenous hydration enhances renal clearance and reduces nephrotoxicity.
• Concurrent medications: Agents that compete for renal tubular secretion (e.g., loop diuretics) may alter clearance.
• Dose density: Shorter intervals between cycles can increase cumulative toxicity but may improve tumour control.
• Genetic polymorphisms: Variations in glutathione S‑transferase genes influence detoxification capacity.

Clinical Significance

Relevance to Drug Therapy

Cisplatin has maintained a pivotal role in combination regimens for numerous malignancies. Its high potency against rapidly dividing cells, coupled with a manageable toxicity profile when appropriately mitigated, supports its continued use. However, dose limitations imposed by nephrotoxicity and ototoxicity necessitate vigilant monitoring and supportive measures.

Practical Applications

Standard dosing schedules vary by tumour type but commonly involve 100–120 mg m⁻² administered intravenously every 3–4 weeks. Dose reductions are considered in cases of pre‑existing renal impairment or significant toxicity. Hydration protocols typically involve 1–2 L of isotonic saline over 6–12 hours before and after infusion, accompanied by diuretic administration (e.g., furosemide) to promote diuresis.

Nephroprotection strategies include the use of sodium thiosulfate or magnesium supplementation, although evidence supporting their efficacy remains variable. Ototoxicity monitoring is facilitated by audiometric testing before, during, and after therapy. Peripheral neuropathy is monitored clinically, with duloxetine or gabapentin considered for symptomatic relief.

Clinical Applications/Examples

Case Scenario 1: Testicular Cancer

A 28‑year‑old man presents with a left testicular mass. Imaging confirms a seminoma. The standard first‑line therapy involves a bleomycin, etoposide, and cisplatin (BEP) regimen. The cisplatin component is administered at 100 mg m⁻² on days 1, 8, and 15 of a 28‑day cycle. Hydration with 2 L of saline and furosemide pre‑infusion reduces nephrotoxicity risk. Audiologic assessment at baseline and after each cycle guides dose adjustments.

Case Scenario 2: Advanced Lung Cancer

A 65‑year‑old woman with stage IV non‑small cell lung cancer is started on a carboplatin‑paclitaxel regimen due to impaired renal function (eGFR < 60 mL min⁻¹ 1.73 m⁻²). Carboplatin dosing is calculated using the Calvert formula: Dose (mg) = Target AUC × (GFR + 15). Here, AUC = 5 mg min L⁻¹ yields a dose of ≈ 260 mg. The clinician chooses carboplatin over cisplatin to avoid exacerbating renal insufficiency.

Problem‑Solving Approach to Ototoxicity

1. Baseline audiometry to establish hearing thresholds.
2. Use of cochlear‑protective agents (e.g., magnesium sulfate) during infusion, though evidence is mixed.
3. Consider dose adjustment or substitution with alternative platinum agents (e.g., carboplatin) if hearing loss progresses beyond 25 dB in any frequency.
4. Referral to audiology and implementation of hearing aids or cochlear implants if necessary.

Summary / Key Points

• Cisplatin is a cis‑diammineplatinum(II) complex that exerts antitumour effects primarily via DNA cross‑linking.
• Pharmacokinetics: Biphasic distribution, renal clearance, and large volume of distribution.
• Pharmacodynamics: Efficacy correlates with AUC; dose–response follows a sigmoidal relationship.
• Major toxicities: Nephrotoxicity, ototoxicity, and peripheral neuropathy; mitigated by hydration, diuretics, and monitoring.
• Clinical applications: Widely used in testicular, ovarian, lung, head and neck, and bladder cancers.
• Key formulas: Cl = Dose ÷ AUC; Dose (mg) = Target AUC × (GFR + 15) for carboplatin; E = E_max × (C_max ÷ (C_max + EC₅₀)).
• Clinical pearls: Adequate hydration reduces nephrotoxicity; audiometric monitoring is essential; dose adjustments based on renal function and toxicity profile.

Mastery of cisplatin pharmacology equips pharmacy and medical students with the knowledge necessary to optimize therapeutic outcomes while minimizing adverse effects in oncology practice.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.